Federal Register Notice: FDA is extending the comment period for the draft guidance Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products that appeared in the 7/2 Federal Register. Comments should be submitted by 5/9. To view this notice, click here.
